Affordable Access

Access to the full text

Whole pelvis radiotherapy for pathological node-positive prostate cancer

Authors
  • Poelaert, Filip1
  • Fonteyne, Valérie2
  • Ost, Piet2
  • De Troyer, Bart3
  • Decaestecker, Karel1
  • De Meerleer, Gert4
  • De Visschere, Pieter5
  • Claeys, Tom1
  • Dhondt, Bert1
  • Lumen, Nicolaas1
  • 1 Ghent University Hospital, Department of Urology, De Pintelaan 185, Ghent, 9000, Belgium , Ghent (Belgium)
  • 2 Ghent University Hospital, Department of Radiation Oncology, Ghent, Belgium , Ghent (Belgium)
  • 3 AZ Nikolaas, Department of Urology, Sint-Niklaas, Belgium , Sint-Niklaas (Belgium)
  • 4 University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium , Leuven (Belgium)
  • 5 Ghent University Hospital, Department of Radiology, Ghent, Belgium , Ghent (Belgium)
Type
Published Article
Journal
Strahlentherapie und Onkologie
Publisher
Springer Berlin Heidelberg
Publication Date
Jan 18, 2017
Volume
193
Issue
6
Pages
444–451
Identifiers
DOI: 10.1007/s00066-016-1094-5
Source
Springer Nature
Keywords
License
Yellow

Abstract

PurposeThe goal of this work was to investigate the oncological outcome of whole pelvis radiotherapy (wpRT) in pathologic pelvic lymph node-positive (pN1) prostate cancer (PCa), evaluate the location of relapse, and identify potential prognostic factors.Patients and methodsAll patients undergoing pelvic lymph node dissection (PLND) since the year 2000 at a single tertiary care center were evaluated. A total of 154 patients with pN1 PCa were treated with wpRT (39 in an adjuvant setting) and 2–3 years of androgen deprivation therapy (ADT). Kaplan–Meier analysis was performed to estimate biochemical recurrence-free survival (bRFS), clinical progression-free survival (cPFS), and prostate cancer-specific survival (CSS). Uni- and multivariate regression analyses were performed to identify prognostic factors.ResultsEstimated bRFS was 67%, cPFS was 71%, and CSS was 96% at 5 years. Median follow-up was 55 months (interquartile range 25–87). Multivariate analysis identified having only 1 positive lymph node, a shorter time between diagnosis and PLND, and older age as independent favorable prognostic factors for biochemical and clinical recurrence. The number of positive lymph nodes was prognostic for CSS (hazard ratio [HR] 1.34, 95% confidence interval 1.17–1.54) and OS (HR 1.22, 95% confidence interval 1.10–1.36). Bone metastases were the most frequent location of PCa relapse (n = 32, 64%).ConclusionsPatients with pN1 PCa treated with wpRT and 2–3 years ADT have an encouraging 5‑year CSS. Understaging of the disease extent may be the most important enemy in definitive pN1 PCa treatment.

Report this publication

Statistics

Seen <100 times